Correction: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway

• Published in: Journal of experimental & clinical cancer research 2023-09, Vol.42 (1), p.1-241, Article 241
• Main Authors: Peng, Yulin, Wang, Yan, Tang, Ning, Sun, Dongdong, Lan, Yulong, Yu, Zhenlong, Zhao, Xinyu, Feng, Lei, Zhang, Baojing, Jin, Lingling, Yu, Fabiao, Ma, Xiaochi, Lv, Chuanzhu
• Format: Article
• Language: English
• Subjects: Angiogenesis; Breast cancer; Vascular endothelial growth factor
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-023-02818-7

Data were represented as percentage of vehicle-treated control. b The expression level of COX-2 protein was analyzed by Western blot HUVECs treated with the indicated doses of Andro for 48 h, with or without VEGF induction. c-d Effects of Andro on tube formation on Matrigel c at 6 h (Original magnifcation, 50 ×), and sprouting from modifed human endothelial cell spheroids d at 24 h (Original magnifcation, 200 ×). Solvent; *P < 0.05, **P < 0.01, Andro treatment vs vehicle control groups) Full size image Fig. 8 figure 2 Effect of Andro on tumor growth and tumor angiogenesis in a breast cancer mouse model. An orthotopic mouse model of human breast cancer MDA-MB-231 cells was used to evaluate the anti-tumor effect of Andro.